A Phase 3 interventional study of Entecavir and Entecavir + Tenofovir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 68 sites in 13 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-03-15.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 2nd largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2007, is one of 13 in phase 3, and was the 8th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 669 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 in phase 3, and was the 8th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. Safety will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TDF=tenofovir
Drug: Entecavir
ETV=entecavir; TDF=tenofovir
Drug: Entecavir + Tenofovir
Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96
HBV DNA levels \<50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
Time frame: At Week 96
Percentage of Participants Who Achieved HBV DNA Levels <50 IU/mL by PCR at Week 48 and Week 96 by Hepatitis B e Antigen (HBeAg) Status
HBV DNA levels \<50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
Time frame: At Weeks 48 and 96
Percentage of Participants Who Achieved HBV DNA Levels <LOQ by PCR at Weeks 48 and 96
LOQ=lower limit of quantitation. LOQ=29 IU/mL, or approximately 169 copies/mL. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
Time frame: At Weeks 48 and 96
Percentage of Participants Who Achieved HBV DNA Levels <LOD by PCR at Weeks 48 and 96
LOD=Lower limit of detection. LOD) LOD=10 IU/mL, or approximately 58 copies/mL. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
Time frame: At Weeks 48 and 96
Mean Log 10 HBV DNA at Weeks 48 and 96
HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan - HPS assay. Reduction in Log 10 HBV count=reduced viral load.
Time frame: Baseline, Weeks 48 and 96
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48 and 96
ALT normalization= ≤1\*upper limit of normal (ULN). Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
Time frame: At Weeks 48 and 96
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48 and 96
HBeAg is a hepatitis B viral protein and is an indicator of active viral replication. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
Time frame: At Weeks 48 and 96
Percentage of Participants With HBeAg Seroconversion [( at Weeks 48 and 96
HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication.
Time frame: At Weeks 48 and 96
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48 and 96
HBsAg = A part of the hepatitis B virus. When found in the blood, HBsAg is an early marker of infection. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
Time frame: At Weeks 48 and 96
Percentage of Participants With HBsAg Seroconversion at Weeks 48 and 96
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection.
Time frame: At Weeks 48 and 96
Number of Participants With HBV DNA in Relevant Categories at Weeks 48 and 96
Using the Roche COBAS TaqMan - HPS assay. Lower limit of Quantitation (LOQ) is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.
Time frame: At Weeks 48 and 96
Number of Participants With Adverse Events, Serious Adverse Events, and Discontinuations From Study Drug Due to Adverse Events or Laboratory Abnormalities
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded.
Time frame: From enrollment through Week 100 + 24-week follow-up
Number of Participants With HBV Resistance Through Week 48
ETVr=entecavir resistance; TDFr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used.
Time frame: Week 48
Number of Participants With HBV Resistance at Week 96
ETVr=entecavir resistance; TFDr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used.
Time frame: Week 96
Number of Participants With Virologic Breakthrough at Week 48
ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough= confirmed \>= 1 log10 increase in HBV DNA from the on-treatment nadir
Time frame: Week 48
Number of Participants With Virologic Breakthrough at Week 96
ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough=confirmed \>=1 log10 increase in HBV DNA from moving nadir
Time frame: Week 96
| Milestone | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Started | 182 | 197 |
| Completed | 176 | 185 |
| Not completed | 6 | 12 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lost to follow-up | 5 | 2 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Poor compliance/noncompliance | 0 | 3 |
| Withdrew: Pregnancy | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Started | 176 | 185 |
| Completed | 170 | 174 |
| Not completed | 6 | 11 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Other | 2 | 0 |
| Withdrew: Poor compliance/noncompliance | 0 | 1 |
| Withdrew: Pregnancy | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
HBV DNA levels \<50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96 | 76.4 | 83.2 |
HBV DNA levels \<50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| HBeAg+ at Week 48 (n=126, n=138) | 61.1 | 74.6 |
| HBeAg- at Week 48 (n=56, n=59) | 91.1 | 93.2 |
| HBeAg+ at Week 96 (n=126, n=138) | 69.8 | 80.4 |
| HBeAg- at Week 96 (n=56, n=59) | 91.1 | 89.8 |
LOQ=lower limit of quantitation. LOQ=29 IU/mL, or approximately 169 copies/mL. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Overall at Week 48 | 67.6 | 74.6 |
| Overall at Week 96 | 74.7 | 81.7 |
LOD=Lower limit of detection. LOD) LOD=10 IU/mL, or approximately 58 copies/mL. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Overall at Week 48 | 58.2 | 66.0 |
| Overall at Week 96 | 68.1 | 76.6 |
HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan - HPS assay. Reduction in Log 10 HBV count=reduced viral load.
| log10 copies/mL | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Baseline (n=182, 197) | 7.48 ± 0.109 | 7.53 ± 0.100 |
| Overall at Week 48 (n=176, 180) | 1.88 ± 0.065 | 1.56 ± 0.026 |
| Overall at Week 96 (n=165, 170) | 1.68 ± 0.048 | 1.51 ± 0.038 |
ALT normalization= ≤1\*upper limit of normal (ULN). Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Overall at Week 48 | 83.0 | 72.6 |
| Overall at Week 96 | 81.9 | 68.0 |
HBeAg is a hepatitis B viral protein and is an indicator of active viral replication. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Week 48 | 25.4 | 19.6 |
| Week 96 | 3.97 | 29.7 |
HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Week 48 | 22.2 | 18.1 |
| Week 96 | 32.5 | 21.7 |
HBsAg = A part of the hepatitis B virus. When found in the blood, HBsAg is an early marker of infection. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints.
| Percent of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Week 48 | 3.2 | 1.4 |
| Week 96 | 4.0 | 5.1 |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Week 48 | 0.8 | 0.7 |
| Week 96 | 1.6 | 2.9 |
Using the Roche COBAS TaqMan - HPS assay. Lower limit of Quantitation (LOQ) is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.
| Percentage of participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| < LOQ (29 IU/mL) at Week 48 | 67.6 | 74.6 |
| LOQ - <50 IU/mL at Week 48 | 2.7 | 5.6 |
| 50 - <172 IU/mL at Week 48 | 7.1 | 6.6 |
| 172 - <1720 IU/mL at Week 48 | 7.7 | 4.1 |
| 1720 - <17,200 IU/mL at Week 48 | 9.3 | 0.5 |
| 17,200 - <172,000 IU/mL at Week 48 | 1.6 | 0 |
| ≥172,000 IU/mL at Week 48 | 0.5 | 0 |
| Missing at Week 48 | 3.3 | 8.6 |
| < LOQ (29 IU/mL) at Week 96 | 74.7 | 81.7 |
| LOQ - <50 IU/mL at Week 96 | 1.6 | 1.5 |
| 50 - <172 IU/mL at Week 96 | 3.3 | 1.0 |
| 172 - <1720 IU/mL at Week 96 | 5.5 | 1.5 |
| 1720 - <17,200 IU/mL at Week 96 | 4.9 | 0 |
| 17,200 - <172,000 IU/mL at Week 96 | 0.5 | 0 |
| ≥172,000 IU/mL at Week 96 | 0 | 0.5 |
| Missing at Week 96 | 9.3 | 13.7 |
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded.
| Participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| Deaths | 0 | 3 |
| SAEs | 12 | 14 |
| Adverse events | 132 | 131 |
| Discontinuations due to AEs | 2 | 5 |
| Related AEs | 39 | 49 |
ETVr=entecavir resistance; TDFr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used.
| Participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| ETVr | 0 | 0 |
| TDFr | 0 | 0 |
ETVr=entecavir resistance; TFDr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used.
| Participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| ETVr | 0 | 0 |
| TDFr | 0 | 0 |
ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough= confirmed \>= 1 log10 increase in HBV DNA from the on-treatment nadir
| Participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| ETVr | 0 | 0 |
| TDFr | 0 | 0 |
ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough=confirmed \>=1 log10 increase in HBV DNA from moving nadir
| Participants | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg |
|---|---|---|
| ETVr | 0 | 0 |
| TDFr | 0 | 0 |
Collected over Week 0 to Week 100 (on study), Post-dosing follow-up - 24 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETV 0.5 mg | — | 13/182 (7.1%) | 69/182 (37.9%) |
| ETV/TDF 0.5 mg +TDF 300 mg | — | 14/197 (7.1%) | 73/197 (37.1%) |
| Event | ETV 0.5 mg | ETV/TDF 0.5 mg +TDF 300 mg |
|---|---|---|
| HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/182 | 0/197 |
| TRAUMATIC BRAIN INJURYInjury, poisoning and procedural complications | 0/182 | 2/197 |
| ACUTE PSYCHOSISPsychiatric disorders | 1/182 | 0/197 |
| OVARIAN CYSTReproductive system and breast disorders | 1/182 | 0/197 |
| CEREBRAL ISCHAEMIANervous system disorders | 1/182 | 0/197 |
| CEREBROVASCULAR ACCIDENTNervous system disorders | 1/182 | 0/197 |
| CHOLELITHIASISHepatobiliary disorders | 1/182 | 0/197 |
| DIABETIC COMPLICATIONMetabolism and nutrition disorders | 1/182 | 0/197 |
| BLOOD AMYLASE INCREASEDInvestigations | 1/182 | 0/197 |
| GASTRIC CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/182 | 0/197 |
| Event | ETV 0.5 mg | ETV/TDF 0.5 mg +TDF 300 mg |
|---|---|---|
| HEADACHENervous system disorders | 19/182 | 22/197 |
| NAUSEAGastrointestinal disorders | 9/182 | 20/197 |
| NASOPHARYNGITISInfections and infestations | 11/182 | 18/197 |
| BACK PAINMusculoskeletal and connective tissue disorders | 13/182 | 9/197 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 13/182 | 8/197 |
| DIARRHOEAGastrointestinal disorders | 11/182 | 13/197 |
| COUGHRespiratory, thoracic and mediastinal disorders | 7/182 | 13/197 |
| FATIGUEGeneral disorders | 11/182 | 12/197 |
| Age, Customized(Participants) | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg | Total |
|---|---|---|---|
| 16 - 20 years | 13 | 19 | 32 |
| 21 - 64 years | 157 | 169 | 326 |
| >=65 years | 12 | 9 | 21 |
| Sex: Female, Male(Participants) | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg | Total |
|---|---|---|---|
| Female | 66 | 51 | 117 |
| Male | 116 | 146 | 262 |
| Race/Ethnicity, Customized(Participants) | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg | Total |
|---|---|---|---|
| Asian | 84 | 102 | 186 |
| Black/African American | 10 | 4 | 14 |
| Native Hawaiian/Other Pacific Islander | 1 | 1 | 2 |
| White | 83 | 87 | 170 |
| Other | 4 | 3 | 7 |
| Country(participants) | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg | Total |
|---|---|---|---|
| United States | 35 | 43 | 78 |
| Turkey | 11 | 11 | 22 |
| Russian Federation | 24 | 23 | 47 |
| Italy | 12 | 15 | 27 |
| India | 5 | 9 | 14 |
| France | 8 | 5 | 13 |
| Canada | 29 | 33 | 62 |
| Argentina | 12 | 15 | 27 |
| Poland | 15 | 13 | 28 |
| Brazil | 5 | 3 | 8 |
| Australia | 24 | 24 | 48 |
| South Africa | 2 | 3 | 5 |
| Region(Participants) | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg | Total |
|---|---|---|---|
| Africa | 2 | 3 | 5 |
| Asia | 29 | 33 | 62 |
| Europe | 70 | 67 | 137 |
| North America | 64 | 76 | 140 |
| South America | 17 | 18 | 35 |
| Hepatitis B e antibody (HBeAb) at baseline(Participants) | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg | Total |
|---|---|---|---|
| Positive | 60 | 60 | 120 |
| Negative | 122 | 137 | 259 |
| Hepatitis B e antigen (HBeAg) status at baseline(Participants) | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg | Total |
|---|---|---|---|
| Positive (> 172,000 IU/mL; approx 10^6 copies/mL) | 126 | 138 | 264 |
| Negative (> 17,200 IU/mL; approx 10^5 copies/mL) | 56 | 59 | 115 |
| Hepatitis B surface antigen (HBsAg) status at baseline(Participants) | ETV 0.5 mg | ETV 0.5 mg +TDF 300 mg | Total |
|---|---|---|---|
| Positive | 182 | 196 | 378 |
| Negative | 0 | 1 | 1 |
The record gives a start of Apr 2007, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Entecavir · Tenofovir